Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roch Houot

Showing results (1-10 of 230) with videos related to

Pageof 23
Sort By:
Bulletin Du Cancer|December 18, 2021
[CAR-T cells in lymphomas: Current and evolving role]Ondine Messéant, Roch Houot
Blood|October 23, 2008
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapyRoch Houot, Ronald Levy
Blood Reviews|October 28, 2008
Vaccines for lymphomas: idiotype vaccines and beyondRoch Houot, Ronald Levy
Leukemia & Lymphoma|January 28, 2009
Idiotype vaccination for lymphoma: moving towards optimisationRoch Houot, Ronald Levy
Clinical Case Reports|June 8, 2017
"Chronic myelogenous leukemia in primary blast crisis" rather than "de novo <i>BCR-ABL1</i>-positive acute myeloid leukemia"Cedric Pastoret, Roch Houot
Haematologica|September 19, 2024
Chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma"Gilles Crochet, Roch Houot
La Revue Du Praticien|May 31, 2012
[Malignant lymphoma]Roch Houot, Thierry Lamy
Blood|May 15, 2025
CARs in pole position: ready for the race?Guillaume Manson, Roch Houot
Oncoimmunology|January 23, 2015
CD137 stimulation enhances the vaccinal effect of anti-tumor antibodiesRoch Houot, Holbrook Kohrt
Hemasphere|October 21, 2024
Promoting and supporting leadership in hematology departmentsRoch Houot, Emmanuel Gyan
Pageof 23

Showing results (1-10 of 230) with videos related to

Sort By:
Pageof 23
Bulletin Du Cancer|December 18, 2021
[CAR-T cells in lymphomas: Current and evolving role]Ondine Messéant, Roch Houot
Blood|October 23, 2008
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapyRoch Houot, Ronald Levy
Blood Reviews|October 28, 2008
Vaccines for lymphomas: idiotype vaccines and beyondRoch Houot, Ronald Levy
Leukemia & Lymphoma|January 28, 2009
Idiotype vaccination for lymphoma: moving towards optimisationRoch Houot, Ronald Levy
Clinical Case Reports|June 8, 2017
"Chronic myelogenous leukemia in primary blast crisis" rather than "de novo <i>BCR-ABL1</i>-positive acute myeloid leukemia"Cedric Pastoret, Roch Houot
Haematologica|September 19, 2024
Chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma"Gilles Crochet, Roch Houot
La Revue Du Praticien|May 31, 2012
[Malignant lymphoma]Roch Houot, Thierry Lamy
Blood|May 15, 2025
CARs in pole position: ready for the race?Guillaume Manson, Roch Houot
Oncoimmunology|January 23, 2015
CD137 stimulation enhances the vaccinal effect of anti-tumor antibodiesRoch Houot, Holbrook Kohrt
Hemasphere|October 21, 2024
Promoting and supporting leadership in hematology departmentsRoch Houot, Emmanuel Gyan
Pageof 23